CeriBell (NASDAQ:CBLL) Posts Quarterly Earnings Results, Misses Estimates By $0.13 EPS

CeriBell (NASDAQ:CBLL) released its quarterly earnings results on Monday. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.13), FiscalAI reports. The company had revenue of $26.49 million during the quarter, compared to analyst estimates of $26.09 million. CeriBell had a negative net margin of 63.51% and a negative return on equity of 36.84%.

Here are the key takeaways from CeriBell’s conference call:

• Q1 revenue was $26.5 million, up 29% year-over-year and 7% sequentially, and management raised full-year 2026 guidance to $112–$116 million (up ~$1M), implying 26%–30% growth.
• Commercial momentum: the active account base reached 680 hospitals with a company-best 33 net additions in the quarter, record headband utilization per account, and improving salesforce productivity (85%+ of hires with ?12 months contributed to the account base).
• Platform expansion: Ceribell initiated commercial launches for neonate and pediatric products after successful pilots and activated a delirium pilot following FDA 510(k) clearance; CMS proposed an NTAP of up to $2,171 per patient, which—if finalized—could materially support adoption and reimbursement.
• Strong unit economics and cash position: gross margin was 87% in Q1 and management expects to sustain high?80s margins as Vietnam production ramps, while cash and securities totaled $141.2 million with a stated objective of reaching cash?flow breakeven.
• Profitability pressure: operating expenses rose 36% to $43.9 million and net loss widened to $19.7 million, with $5.6 million of Q1 G&A tied to IP litigation that management expects to keep legal spend elevated into Q2, creating near?term expense headwinds.

CeriBell Stock Performance

NASDAQ CBLL traded up $0.67 on Wednesday, hitting $17.42. 350,860 shares of the stock were exchanged, compared to its average volume of 316,813. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.73 and a quick ratio of 9.35. The business’s fifty day moving average is $19.17 and its 200 day moving average is $18.84. CeriBell has a 52 week low of $10.85 and a 52 week high of $24.33. The company has a market capitalization of $659.73 million, a PE ratio of -10.71 and a beta of 0.99.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Canaccord Genuity Group reduced their price target on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a report on Tuesday. BTIG Research reiterated a “buy” rating and issued a $30.00 price target on shares of CeriBell in a report on Wednesday, January 28th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of CeriBell in a report on Monday, April 6th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, CeriBell has a consensus rating of “Moderate Buy” and a consensus price target of $22.20.

Insider Activity

In other CeriBell news, Director Josef Parvizi sold 16,714 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $20.27, for a total transaction of $338,792.78. Following the sale, the director directly owned 722,652 shares of the company’s stock, valued at approximately $14,648,156.04. This represents a 2.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CTO Raymond Woo sold 11,104 shares of the company’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $20.44, for a total transaction of $226,965.76. Following the sale, the chief technology officer directly owned 197,648 shares in the company, valued at $4,039,925.12. This trade represents a 5.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 175,119 shares of company stock valued at $3,310,772. 20.10% of the stock is owned by insiders.

Institutional Trading of CeriBell

Several institutional investors and hedge funds have recently added to or reduced their stakes in CBLL. Russell Investments Group Ltd. raised its position in shares of CeriBell by 41.4% in the fourth quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock valued at $64,000 after purchasing an additional 854 shares during the period. Caitong International Asset Management Co. Ltd raised its position in shares of CeriBell by 3,971.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after purchasing an additional 1,231 shares during the period. Deutsche Bank AG raised its position in shares of CeriBell by 1.7% in the fourth quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock valued at $1,868,000 after purchasing an additional 1,393 shares during the period. Royal Bank of Canada raised its position in shares of CeriBell by 10.8% in the fourth quarter. Royal Bank of Canada now owns 15,588 shares of the company’s stock valued at $342,000 after purchasing an additional 1,514 shares during the period. Finally, Invesco Ltd. raised its position in shares of CeriBell by 15.5% in the fourth quarter. Invesco Ltd. now owns 12,037 shares of the company’s stock valued at $264,000 after purchasing an additional 1,618 shares during the period.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.